Beiersdorf and Rubedo Life Science have announced a multi-year agreement to offer innovative anti-ageing solutions. This merger, as the German company points out, will also see Rubedo become an investor after having participated in a Series A financing round through an equity fund.
The objective of this collaboration, as Beiersdorf explains, is to leverage Rubedo's cutting-edge research in the field of cellular senescence and Beiersdorf's market presence to develop innovative anti-ageing products.
‘The collaboration revolves around the exploration of novel compounds derived from Rubedo's extensive research programmes, specifically targeting cellular senescence. Senescent cells accumulate with age and cause inflammation, which can contribute to age-related skin changes and pathologies. These compounds will come from Rubedo's topical dermatology programme, which have senolytic and anti-inflammatory properties,’ explained Beiersrdof.
Rubedo CEO Marco Quarta said: ‘We are delighted to announce the collaboration with Beiersdorf, a recognised global leader in the cosmetics and skincare industry, to develop new products that address skin ageing. Combining our expertise with Beiersdorf can revolutionise the skincare landscape, offering consumers new solutions that address cellular ageing for healthy skin."
For Beiersdorf, Dr. Gitta Neufang, Senior Vice President Corporate Global R&D, explained that they see Rubedo as an opportunity with great potential in the field of senescence to develop superior skin rejuvenation solutions.